- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02221336
Daily Subjective and Objective Smartphone Measures of Illness Activity to Treat Bipolar Disorder- The MONARCA II Trial (MONARCAII)
Daily Electronic Monitoring of Subjective and Objective Measures of Illness Activity in Bipolar Disorder - The MONARCA II Trial (MONitoring, treAtment and pRediCtion of bipolAr Disorder Episodes II)
Bipolar disorder is associated with a high risk of relapse and hospitalisation and many patients do not recover to their previous psychosocial function. Major reasons for poor outcomes are delayed intervention for prodromal depressive and manic symptoms as well as decreased adherence with treatment.
Recently, in the MONARCA I trial (NCT01446406), the investigators developed and deployed a smartphone based self-monitoring system (the MONARCA I system) in a randomized controlled trial, to test the effect of daily reporting of subjective self-monitoring of depressive and manic symptoms as well as a bi-directional feedback loop on depressive and manic symptoms.
In the MONARCA II trial the investigators will develop and deploy a new version of the smartphone based monitoring system. The investigators will in a randomized controlled single blind trial investigate whether daily electronic monitoring of subjective and objective measures of illness activity using a smartphone based self-monitoring system including feedback on subjective as well as automatically generated objective data (e.g.social activity, physical activity etc.) (the MONARCA II system) reduces the severity of depressive and manic symptoms and improves functioning more than a control group receiving a smartphone. All patients will be followed for 9 months with outcome assessments at baseline, after 4 weeks, after 3 months, after 6 months and after 9 months.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Copenhagen, Denmark, 2100
- Psychiatric Centre Copenhagen, Rigshospitalet
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Bipolar Disorder according to SCAN interview
- ≥18 years of age
- Patients who previously have received a course of treatment at the Clinic for Affective Disorders, Psychiatric Centre Copenhagen, Denmark
Exclusion Criteria:
- Pregnancy
- Lack of Danish language skills
- Patients who previously have received and used the MONARCA I system for self-monitoring
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Non-MONARCA II system
Use of smartphone for normal communicative purposes only.
No self-monitoring and no feedback loop.
|
Daily use of smartphone for normal communicative purposes.
No self-monitoring in the MONARCA II system.
|
|
Experimental: The MONARCA II system
Daily electronic monitoring of subjective and objective smartphone measures including a feedback loop
|
Daily electronic monitoring of subjective and objective smartphone measures including a feedback loop
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Differences between the groups in depressive and manic symptoms and the number of affective episodes
Time Frame: Baseline and up to 9 months
|
Differences between the groups in depressive and manic symptoms measured using Hamilton Depression Rating Scale (HDRS) and Young Mania Rating Scale (YMRS) and episodes defined ad HDRS<= 14 and/or YMRS<= 14
|
Baseline and up to 9 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Differences between the groups in smartphone measures
Time Frame: Baseline and up to 9 months
|
Differences between the groups in: -Automatically generated objective smartphone measures |
Baseline and up to 9 months
|
|
Differences between the groups in number of hospitalizations
Time Frame: Baseline up to 9 months follow up
|
Differences between the groups in number of hospitalization
|
Baseline up to 9 months follow up
|
|
Differences between the groups in number of contacts to clinicians and emergency rooms
Time Frame: Baseline up to 9 months follow up
|
Differences between the groups in number of contacts to clinicians and emergency rooms
|
Baseline up to 9 months follow up
|
|
Differences between the groups in functioning
Time Frame: Baseline up to 9 months follow up
|
Differences between the groups in functioning measured using the FAST questionnaire
|
Baseline up to 9 months follow up
|
|
Differences between the groups in perceived stress
Time Frame: Baseline up to 9 months
|
Differences between the groups in perceived stress using the perceived stress questionnaire
|
Baseline up to 9 months
|
|
Differences between the groups in quality of life
Time Frame: Baseline up to 9 months follow up
|
Differences between the groups in quality of life measured using the WHOQoL questionnaire
|
Baseline up to 9 months follow up
|
|
Differences between the groups in self-rated depressive symptoms
Time Frame: Baseline up to 9 months
|
Differences between the groups in self-rated depresisve symptoms using the BDI questionnaire
|
Baseline up to 9 months
|
|
Differences in self-rated manic symptoms
Time Frame: Baseline up to 9 months follow up
|
Differences between the groups in self-rated manic symptoms using the ASRM questionnaire
|
Baseline up to 9 months follow up
|
|
Differences between the groups in adherence to medication
Time Frame: Baseline up to 9 months follow up
|
Differences between the groups in adherence to medication measured using the questionnaire MARS
|
Baseline up to 9 months follow up
|
|
Differences between the groups in recovery
Time Frame: Baseline up to 9 months follow up
|
Differences between the groups in recovery using the questionnaire Recovery Assessment Scale (RAS)
|
Baseline up to 9 months follow up
|
|
Differences between the groups in empowerment
Time Frame: baseline up ot 9 months
|
Differences between the groups in empowerment using the questionnaire Rogers Empowerment scale.
|
baseline up ot 9 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Maria Faurholt-Jepsen, MD, Psychiatric Centre Copenhagen, Rigshospitalet, Denmark
Publications and helpful links
General Publications
- Faurholt-Jepsen M, Frost M, Christensen EM, Bardram JE, Vinberg M, Kessing LV. Validity and characteristics of patient-evaluated adherence to medication via smartphones in patients with bipolar disorder: exploratory reanalyses on pooled data from the MONARCA I and II trials. Evid Based Ment Health. 2020 Feb;23(1):2-7. doi: 10.1136/ebmental-2019-300106.
- Faurholt-Jepsen M, Frost M, Vinberg M, Christensen EM, Bardram JE, Kessing LV. Smartphone data as objective measures of bipolar disorder symptoms. Psychiatry Res. 2014 Jun 30;217(1-2):124-7. doi: 10.1016/j.psychres.2014.03.009. Epub 2014 Mar 13.
- Faurholt-Jepsen M, Vinberg M, Christensen EM, Frost M, Bardram J, Kessing LV. Daily electronic self-monitoring of subjective and objective symptoms in bipolar disorder--the MONARCA trial protocol (MONitoring, treAtment and pRediCtion of bipolAr disorder episodes): a randomised controlled single-blind trial. BMJ Open. 2013 Jul 24;3(7):e003353. doi: 10.1136/bmjopen-2013-003353. Print 2013.
- Faurholt-Jepsen M, Frost M, Busk J, Christensen EM, Bardram JE, Vinberg M, Kessing LV. Differences in mood instability in patients with bipolar disorder type I and II: a smartphone-based study. Int J Bipolar Disord. 2019 Feb 1;7(1):5. doi: 10.1186/s40345-019-0141-4.
- Faurholt-Jepsen M, Vinberg M, Frost M, Christensen EM, Bardram J, Kessing LV. Daily electronic monitoring of subjective and objective measures of illness activity in bipolar disorder using smartphones--the MONARCA II trial protocol: a randomized controlled single-blind parallel-group trial. BMC Psychiatry. 2014 Nov 25;14:309. doi: 10.1186/s12888-014-0309-5.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- H-2-2014-059
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bipolar Disorder
-
ProgenaBiomeWithdrawnBipolar Disorder | Bipolar I Disorder | Bipolar II Disorder | Bipolar Type I Disorder | Bipolar Disorder Mild | Bipolar Disorder Moderate | Bipolar Disorder SevereUnited States
-
Vielight Inc.Not yet recruitingBipolar Disorder (BD) | Bipolar | Bipolar Disorder DepressionCanada
-
Xenon Pharmaceuticals Inc.RecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II DisorderUnited States
-
Xenon Pharmaceuticals Inc.Enrolling by invitationBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II DisorderUnited States
-
University of Texas Southwestern Medical CenterThe Texas Child Mental Health Care Consortium (TCMHCC)RecruitingBipolar Disorder Family Members | Bipolar Disorder (BD) | Bipolar Disorder I or II | Screening ToolUnited States
-
University of California, Los AngelesUniversity of Colorado, Denver; University of Pittsburgh; University of Cincinnati and other collaboratorsRecruitingAdolescents | Bipolar Disorder (BD) | Bipolar Disorder I or II | Bipolar Disorder NOS | Bipolar Spectrum DisorderUnited States
-
Rush University Medical CenterThe Ryan Licht Sang Bipolar FoundationCompletedBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar Disorder I | Bipolar Affective DisorderUnited States
-
University of PittsburghNational Alliance for Research on Schizophrenia and DepressionCompletedBipolar I Disorder | Bipolar II Disorder | Bipolar Disorder NOSUnited States
-
Babes-Bolyai UniversityRecruitingBipolar Disorder (BD)Romania
-
Korea University Anam HospitalHucircadian; Korea University MedicineEnrolling by invitationMood Disorders | Bipolar Disorder (BD) | Depression - Major Depressive Disorder | Depression BipolarSouth Korea
Clinical Trials on Non-MONARCA II system
-
Psychiatric Centre RigshospitaletUniversity of Copenhagen; IT University of Copenhagen; The European Union, 7.th...CompletedBipolar DisorderDenmark
-
Danone Asia Pacific Holdings Pte, Ltd.Completed
-
TC Erciyes UniversityCompletedPercutaneous NephrolithotomyTurkey
-
Advanced Medical Solutions Ltd.NAMSACompletedWoundUnited Kingdom, South Africa
-
Smith & Nephew, Inc.WithdrawnArthroplasty | Knee | ReplacementSingapore, China, India
-
Bournemouth UniversitySalisbury NHS Foundation TrustCompletedSpinal Cord Injuries | TetraplegiaUnited Kingdom
-
Hoffmann-La RocheCompletedIdiopathic Pulmonary FibrosisUnited States, Belgium, Germany, Peru, Mexico, Poland, France, Italy, United Kingdom, Australia, Canada, Spain, Japan
-
Rigshospitalet, DenmarkCompletedDisorder Related to Lung Transplantation | CLAD, Bronchiolitis ObliteransUnited Kingdom, Belgium, Denmark, Germany, Netherlands, Norway, Sweden
-
MetaCure (USA), Inc.CompletedDiabetes Mellitus, Type 2Austria, Germany, Italy, Poland
-
Stanford UniversityGenentech, Inc.CompletedBronchiolitis Obliterans | Graft Vs Host DiseaseUnited States